Quick Facts: Androfin Therapeutic Uses

• Symptom Management: Helps to improve urinary flow and other symptoms associated with benign prostatic hyperplasia (BPH) in men with an enlarged prostate.
• Risk Reduction: May reduce the risk of a severe complication of BPH known as acute urinary retention.
• Procedure Support: Can reduce the likelihood of needing surgery related to BPH, such as prostatectomy.
• Hair Loss Management: Is also indicated for the management of male pattern hair loss (androgenetic alopecia) in men.

---

What Androfin Treats: Main Uses and Benefits

Androfin is a medication that plays a role in the management of specific conditions in men. Its primary therapeutic domain is addressing symptoms related to benign prostatic hyperplasia (BPH), also known as an enlarged prostate.

For men with an enlarged prostate, treatment with Androfin may help to improve symptoms associated with the condition, such as difficulty starting or stopping urination. Furthermore, it has been observed that this compound may reduce the risk of experiencing acute urinary retention, a severe complication of BPH. Its use can also be associated with a reduced likelihood of needing related surgical procedures.

Additionally, Androfin is indicated for the management of male pattern hair loss (androgenetic alopecia). When used for this purpose, the compound helps to support hair growth and may help to prevent further hair loss.

Androfin (Finasteride) is strictly indicated for use in men only. Its eligibility profile is defined by absolute regulatory contraindications related to sex, age, and reproductive status.

---

Populations Excluded from Use

Category	Regulatory Status
Females (Women)	Contraindicated in all women for any use.
Pregnant Females	Absolutely Contraindicated due to the risk of fetal abnormalities in a male fetus.
Pediatric Population	Not Established for safety and effectiveness; not indicated for children or adolescents (under 18 years).
Hypersensitivity	Contraindicated in patients with known allergy to Finasteride or any component.

---

Age and Condition-Based Eligibility

Category	Regulatory Status
Adult Males	Approved for use in adult men (18+).
Geriatric Patients	No dosage adjustment is necessary in older adults.
Renal Impairment	No dosage adjustment is necessary in patients with kidney problems.
Hepatic Impairment	Caution is advised in patients with liver function abnormalities, as the medicine is extensively metabolized in the liver.

The regulatory profile mandates that pregnant women must not handle crushed or broken tablets due to the risk of absorption and subsequent harm to a male fetus.

The official regulatory profile for Androfin establishes that no drug interactions of clinical importance have been identified in human studies. The overall interaction structure is defined by the low risk of affecting co-administered medicines and a specific restriction against therapeutic duplication.

Finasteride, the active compound, is metabolized extensively in the liver primarily by the Cytochrome P450 3A4 (CYP3A4) enzyme. However, the medicine itself does not appear to affect this drug metabolism system. Compounds that have been tested in man, including antipyrine, digoxin, propranolol, theophylline, and warfarin, resulted in no clinically meaningful interactions with Finasteride.

A necessary constraint is the prohibition on co-administration with other 5-alpha reductase inhibitors to strictly prevent therapeutic duplication. Separately, caution is noted for individuals with hepatic impairment (liver function abnormalities), as plasma concentrations of the medicine may be increased due to its extensive metabolism in the liver and potentially reduced clearance. Official labeling confirms no known interaction with either food or alcohol, indicating that the administration timing is not constrained by meals. The regulatory focus is on the documented low interaction potential and the constraints related to drug class co-use.

1. Selective Inhibition of Type II 5-Alpha Reductase

Androfin (Finasteride) is a selective competitive inhibitor that targets the Type II 5-alpha reductase enzyme (5AR2). The drug forms a stable, persistent bond with 5AR2, physically preventing the enzyme from performing its catalytic function, thereby triggering the subsequent biochemical cascade.

2. Suppression of Dihydrotestosterone (DHT) Synthesis

By inhibiting 5AR2, Androfin dramatically reduces the conversion of the precursor hormone, Testosterone, into the more potent androgen, Dihydrotestosterone (DHT). This systemic and tissue-specific decrease in DHT concentration diminishes hormonal signaling intensity mediated by DHT in target tissues.

3. Modulation of Androgen-Driven Cellular Proliferation

The reduced availability of DHT leads to a corresponding decrease in the trophic (growth-stimulating) signals sent to androgen-sensitive cells. This diminished mitogenic drive results in the modulation of specific tissue size. The suppression is partial, however, due to the drug's lower inhibitory affinity for the Type I 5-alpha reductase isoenzyme.

Androfin is a systemic agent administered by the oral route as a film-coated tablet. The daily dose is determined by the specific clinical context. The standard regimen is once daily (OD) for both available strengths.

---

Dosage and Administration Protocol

There are two distinct dosing protocols for adults:

• The 5 mg tablet is administered once per day for one therapeutic purpose.
• The 1 mg tablet is administered once per day for a separate, distinct purpose.

The administration is not dependent on mealtimes; the tablet may be taken with or without food. For the administration to be correct, the film-coated tablet must be swallowed whole and must not be crushed, broken, or chewed. This physical constraint is critical for proper use.

---

Schedule and Duration

Adherence to a continuous, long-term schedule is a fundamental component of the treatment. For both dosing regimens, a minimum duration of three to six months of continuous daily use is required before the full effects can be accurately assessed. If a dose is forgotten, the standard procedure is to skip the missed dose and take the next dose at the regular time, without attempting to double the dose.

---

Population-Specific Rules

No dosage adjustment is necessary for patients with renal impairment. However, since the compound is metabolized by the liver, caution is noted in patients with liver function abnormalities. This medication is not indicated for use in pediatric patients.

Research Evidence / Overview of Studies

Summary of Antihistamine Activity

Research has explored the drug's activity for allergic rhinitis (e.g., hay fever symptoms). Studies examined whether the drug was associated with a reduction in pain and discomfort associated with hives (urticaria). Research also examined whether the drug was associated with changes in inflammatory markers and observed changes in swelling.

---

Key Clinical Trial Findings

Acute Symptom Management

One key trial evaluated the onset and size of the observed change in symptoms following a single dose, specifically focusing on itching and nasal congestion. Trial results showed that the earliest measured change in symptoms occurred within one hour of administration.

• Dosing: Single-dose administration was the focus of the initial studies examining drug activity.
• Outcome: The primary endpoint evaluated was the magnitude and duration of observed symptom change compared to a placebo.

Long-Term Use and Tolerability

Studies evaluated the tolerability and sustained activity of long-term use for managing chronic urticaria. Findings were gathered over a six-month period.

• Consistency: The research examined whether the drug’s observed effect was maintained over the full study duration.
• Adverse Effects: Data was collected on the incidence of effects reported by participants, including central nervous system impacts such as drowsiness.

---

Comparative Review

Combined research findings were reviewed to understand the drug’s profile in patients experiencing moderate symptoms. This review did not involve a direct head-to-head randomized controlled trial (RCT) against other treatments.

Safety and Patient Profile

Participants reported that this medication was associated with drowsiness, and warnings address operating heavy machinery. Research did not evaluate the drug’s use for insomnia, and the scope of the studies was restricted to the established research dosage.

Common questions about Androfin (FAQ)

---

Q: Does Androfin cause hair loss?

A: Official product information states that Androfin, at the 1 mg strength, is indicated for the treatment of male pattern hair loss (androgenetic alopecia) in men. Regulatory documents describe that the medicine is used to manage and slow the progression of this condition, rather than being a cause of hair loss.

---

Q: Is Androfin known to affect weight?

A: Studies and official safety data have included reports of changes in body weight as a potential adverse reaction. These reports cover both unusual weight gain and weight loss, though they are generally described as less common side effects.

---

Q: Is there a generic version of Androfin available?

A: Yes, Androfin contains the active ingredient Finasteride, which is the internationally recognized name for the compound. According to regulatory databases, this active ingredient is available in generic versions that are approved for the same uses.

---

Q: Does Androfin affect fertility?

A: Postmarketing reports gathered by regulatory bodies have included cases of male infertility and/or poor seminal quality. Official information indicates that the normalization or improvement of seminal quality has been reported in some instances after the medicine was discontinued.

---

Q: What is the risk of stopping Androfin suddenly?

A: Regulatory documents state that when the medicine is discontinued, the therapeutic effects gradually begin to reverse. The biological effect, measured by hormone levels, typically returns to baseline within approximately two weeks to three months. There is no official requirement for tapering the dose upon stopping.

---

Q: How quickly does Androfin leave the system after the last use?

A: Studies show that the mean terminal half-life of the medicine in the body is relatively short. Official information indicates this time is approximately 5 to 6 hours in younger men and about 8 hours in men over 70 years of age.

---

Q: Are there special warnings about Androfin for people with heart conditions?

A: The official safety profile includes information about circulatory system effects. Adverse reaction reports list postural hypotension, which is a drop in blood pressure that can occur when changing position, like standing up quickly.

---

Q: Does Androfin have a specific time of day it should be used?

A: Official guidance confirms the medicine is administered once daily. The product information indicates the dose is best maintained at the same time each day for consistency, but the specific time is not constrained.

---

Q: Are the side effects of Androfin permanent?

A: Official regulatory reports have noted cases where sexual side effects, such as decreased sex drive and erectile dysfunction, have persisted after the drug was discontinued. However, the official documentation does not characterize all side effects as permanent.

---

Q: Does Androfin affect blood pressure?

A: Yes, the official safety profile confirms the medicine has been associated with blood pressure-related side effects. The reported adverse reaction is postural hypotension, which describes a temporary drop in blood pressure when changing positions.

---

Q: How long does the effect of one use of Androfin last?

A: The medicine's half-life for a single dose is short, typically ranging from 5 to 8 hours, and its effect of suppressing the target hormone begins within 24 hours. Because Androfin is intended for long-term therapeutic modulation, its full clinical benefits are achieved through continuous daily administration.

---

Q: Do other medicines have the same active ingredient as Androfin?

A: Yes, Androfin contains the active ingredient Finasteride. Official regulatory information states that this chemical compound is the same active ingredient found in other prescription products prescribed for similar purposes.

---

Q: What are the common benefits reported in clinical trials of Androfin?

A: Clinical trials reviewed by regulatory bodies reported different themes based on the strength used. Studies using the 1 mg strength reported an observed increase in hair count, while trials using the 5 mg strength reported a reduction in prostate size and improved associated symptoms.

Storage and Disposal Requirements

Androfin (Finasteride) must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The medicine must be actively protected from light and moisture, and should not be stored in areas exposed to excessive heat or humidity. To maintain product stability, the tablets must remain in the original container and be kept tightly closed.

As a crucial safety measure, Androfin must be stored out of the sight and reach of children. Furthermore, pregnant women must not handle crushed or broken tablets. Unused or expired medication must be disposed of according to local regulations, often by utilizing a drug take-back program or following specific guidance for household trash disposal, and should not be discarded in wastewater.